Impact of CYP2C9*3/*3 genotype on the pharmacokinetics and pharmacodynamics of piroxicam.
Perini
Jamila A
JA
Suarez-Kurtz
Guilherme
G
D019540:Area Under Curve; D001189:Aryl Hydrocarbon Hydroxylases / Q000235:genetics*; D051545:Cyclooxygenase 1 / Q000378:metabolism; D051546:Cyclooxygenase 2 / Q000378:metabolism; D016861:Cyclooxygenase Inhibitors / Q000097:blood / Q000493:pharmacokinetics; D065729:Cytochrome P-450 CYP2C9; D005838:Genotype; D006207:Half-Life; D006801:Humans; D008657:Metabolic Clearance Rate; D010894:Piroxicam / Q000097:blood / Q000493:pharmacokinetics*; D013997:Time Factors
D016861:Cyclooxygenase Inhibitors; D010894:Piroxicam; C450260:CYP2C9 protein, human; D065729:Cytochrome P-450 CYP2C9; D001189:Aryl Hydrocarbon Hydroxylases; D051545:Cyclooxygenase 1; D051546:Cyclooxygenase 2